Dr. Mohammad Ali Khoshnoodi, MD

Dr. Khoshnoodi practices at Reading Hospital in West Reading, Pennsylvania, part of Tower Health.

Dr. Khoshnoodi's NPI, 1013159326, was assigned on April 1, 2009. Dr. Khoshnoodi holds Maryland license D77423.

Dr. Khoshnoodi's primary practice is Reading Hospital, at 420 S 5th Avenue, West Reading, PA 19611 in Berks County. The practice phone is (610) 988-8000.

Dr. Khoshnoodi's primary practice is Reading Hospital in West Reading, Pennsylvania, part of Tower Health. Dr. Khoshnoodi is also affiliated with The Johns Hopkins Hospital. The medical group on file is Phoenix Physical Therapy. Dmand AI also links Dr. Khoshnoodi to 3 more hospitals, 6 group practices and clinics and 5 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Khoshnoodi practices, 11 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Khoshnoodi's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dmand AI has Dr. Khoshnoodi's licenses on file in 2 states: Maryland and Pennsylvania.

CMS data shows 931 Medicare services from Dr. Khoshnoodi across 15 procedure codes in 2024, for 357 Medicare patients. Medicare paid $56,372 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 357 Medicare patients who saw Dr. Khoshnoodi in 2024. The largest group is 65 to 74, with 169 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 1.64, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Khoshnoodi's median patient age at 64, with 54% women.

In 2024, Dr. Khoshnoodi wrote 1,114 Medicare Part D claims for 230 patients. 91% of them were for generic drugs. CMS names the drug for 950 of them, across 25 drugs with 11 or more claims each, at $566,993 in total drug cost. In 2023, CMS named 590 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Khoshnoodi for performance year 2024, reported as part of a group. CMS lists Dr. Khoshnoodi as offering telehealth.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

CMS Open Payments shows 3 general payments to Dr. Khoshnoodi from 3 drug and device companies from 2019 to 2025. Consulting fees make up the largest share, 88% of the total. Alnylam Pharmaceuticals Inc. paid the most, $360.